1,1-dimethylethyl 2-(2-{[3-(3-chlorophenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazin-7-yl]oxy}ethyl)-1-piperidinecarboxylate | 1192687-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1,1-dimethylethyl 2-(2-{[3-(3-chlorophenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazin-7-yl]oxy}ethyl)-1-piperidinecarboxylate
• 英文别名: tert-butyl 2-[2-[[3-(3-chlorophenyl)-1-oxo-2H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]ethyl]piperidine-1-carboxylate
• CAS: 1192687-64-1
• 化学式: C₂₅H₃₀ClN₃O₄
• 分子量: 471.984
• InChiKey: QIKIOTHRJHXLQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-异丙基氯乙酰氨 、 1,1-dimethylethyl 2-(2-{[3-(3-chlorophenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazin-7-yl]oxy}ethyl)-1-piperidinecarboxylate 在 sodium hydride 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: Novel, potent, and selective series of Vasopressin1b receptor antagonists

  摘要：

  Novel series of pyrrole-pyrazinone and pyrazole-pyrazinone have been identified as potent and selective Vasopressin(1b) receptor antagonists. Exploration of the substitution pattern around the core of these templates allowed generation of compounds with high inhibitory potency at the Vasopressin(1b) receptor, including examples that showed good selectivity with respect to Vasopressin(1a), Vasopressin(2), and Oxytocin receptor subtypes. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.037
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 1,1-dimethylethyl 2-(2-{[3-(3-chlorophenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazin-7-yl]oxy}ethyl)-1-piperidinecarboxylate
  参考文献：
  名称：

  Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: Novel, potent, and selective series of Vasopressin1b receptor antagonists

  摘要：

  Novel series of pyrrole-pyrazinone and pyrazole-pyrazinone have been identified as potent and selective Vasopressin(1b) receptor antagonists. Exploration of the substitution pattern around the core of these templates allowed generation of compounds with high inhibitory potency at the Vasopressin(1b) receptor, including examples that showed good selectivity with respect to Vasopressin(1a), Vasopressin(2), and Oxytocin receptor subtypes. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.037

文献信息

• [EN] PYRROLO [1, 2-A] PYRAZINE DERIVATIVES AS VASOPRESSIN VIB RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLO [1, 2-A] PYRAZINE ANTAGONISTES DES RÉCEPTEURS V1B DE LA VASOPRESSINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009130231A1

  公开（公告）日：2009-10-29

  The present invention relates to novel compounds of formula (I) or salts thereof; wherein R is -X-[CH2]nCR4R5-Y; or a group G; R1 is H or C1 -C4 alkyl; R2 is aryl, heteroaryl or C3-C7 cycloalkyl, which may be substituted with one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, - CN; R3 is -CH2-C(=O)-NH-R6; X is -CR7R8-, -O-, -NR9-, -S-; Y is-NR10R11 R4 is H or C1 -C4 alkyl; R5 is H or C1 -C4 alkyl; R6 is C1-C6 alkyl, C3-C6 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R7 is H or C1 -C4 alkyl; R8 is H or C1 -C4 alkyl; R9 is H or C1 -C4 alkyl; R10 is H or C1-C4 alkyl, or together with R11 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR12; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R11 is H or C1 -C4 alkyl; R12 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; G is one of the groups selected from the list consisting of G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11 and G12; R 13 is H or C1-C4 alkyl, or together with R14 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR24; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R14 R16 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R15, R 17 correspond to H or C1-C4 alkyl and may assume different meanings; R 18 is H or C1-C4 alkyl, or together with R17 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR25; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R19, R20, R21, R22, R23, R24, R25 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R26, R27, R28, R29 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; I, I' correspond to 1 or 2 and may assume different meanings; m, m', m", m"', mιv, mv correspond to 0, 1 or 2 and may assume different meanings; n is 1, 2 or 3; q is 1, 2 or 3; p, p', p", p'" correspond to 0, 1, 2 or 3 and may assume different meanings; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as antagonists of V1b receptors, e.g. to treat depression and anxiety.

  本发明涉及以下式（I）的新化合物或其盐；其中R为-X-[ ]nCR4R5-Y；或者为基团G；R1为H或C1-C4烷基；R2为芳基、杂环芳基或C3-C7环烷基，可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R3为-CH2-C（=O）-NH-R6；X为-CR7R8-、-O-、-NR9-、-S-；Y为-NR10R11；R4为H或C1-C4烷基；R5为H或C1-C4烷基；R6为C1-C6烷基、C3-C6环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R7为H或C1-C4烷基；R8为H或C1-C4烷基；R9为H或C1-C4烷基；R10为H或C1-C4烷基，或者与R11一起形成一个含有O、S和-NR12等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R11为H或C1-C4烷基；R12为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；G为从G1、G2、G3、G4、G5、G6、G7、G8、G9、G10、G11和G12的列表中选择的一种基团；R13为H或C1-C4烷基，或者与R14一起形成一个含有O、S和-NR24等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R14 R16为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R15、R17对应于H或C1-C4烷基，可能具有不同的含义；R18为H或C1-C4烷基，或者与R17一起形成一个含有O、S和-NR25等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R19、R20、R21、R22、R23、R24、R25为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R26、R27、R28、R29为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；I、I'对应于1或2，可能具有不同的含义；m、m'、m"、m"'、mιv、mv对应于0、1或2，可能具有不同的含义；n为1、2或3；q为1、2或3；p、p'、p"、p"'对应于0、1、2或3，可能具有不同的含义；它们的制备方法、在这些方法中使用的中间体、含有它们的药物组合物以及它们作为V1b受体拮抗剂在治疗中的用途，例如用于治疗抑郁症和焦虑症。